Lowest Price Guaranteed
Pages
198
Last Updated
June 2026
View Count
11966
Table of Content
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Introduction
2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative
2.4.2.3. Advantages
2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions
2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Hospitals
2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Oncology Biosimilars Market
6.2.1. Key Characteristics of Oncology Biosimilars Market
6.2.2. Key Applications of the Oncology Biosimilars Market
6.2.3. Challenges Associated with Oncology Biosimilars Market
6.3. Future Perspective
7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. Oncology Biosimilars Providers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Oncology Biosimilars Market: Overall Market Landscape
7.2.4.1. Analysis by Cancer Type
7.2.4.2. Analysis by Drug Class Type
7.2.4.3. Analysis by Route of Administration
7.2.4.4. Analysis by End User
7.2.4.5. Analysis by Distribution Channel
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies
8.4. Company Competitiveness Analysis: Oncology Biosimilars Providers
8.4.1. Oncology Biosimilars Providers Based in North America (Peer Group 1)
8.4.2. Oncology Biosimilars Providers Based in Europe (Peer Group 2)
8.4.3. Oncology Biosimilars Providers Based in Asia-Pacific (Peer Group 3)
8.4.4. Oncology Biosimilars Providers Based in Middle East and North Africa, and Latin America (Peer Group 4)
8.5. Key Findings
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Amgen
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service / Product Portfolio
9.2.4. Recent Developments and Future Outlook
* Similar details are presented for other below mentioned companies based on information in the public domain
9.3. Allergan
9.4. Apotex
9.5. Biogen
9.6. BIOCAD
9.7. Biocon Biologics
9.8. Celltrion Healthcare
9.9. Coherus Biosciences
9.10. Cipla
9.11. Dr. Reddy’s Laboratories
9.12. GlaxoSmithKline
9.13. Intas Pharmaceuticals
9.14. Mylan
9.15. Merck
9.16. Momenta Pharmaceuticals
9.17. Novartis
9.18. Pfizer
9.19. STADA Arzneimittel
9.20. Roche
9.21. Sanofi
9.22. Sandoz International
9.23. Teva Pharmaceutical
10. SWOT ANALYSIS
11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion
12. GLOBAL ONCOLOGY BIOSIMILARS MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Trends Disruption Impacting Market
12.4. Global Oncology Biosimilars Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
12.5. Multivariate Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario
12.6. Key Market Segmentations
13. MARKET OPPORTUNITIES BASED ON TYPE OF CANCER
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Revenue Shift Analysis
13.4. Market Movement Analysis
13.5. Penetration-Growth (P-G) Matrix
13.6. Oncology Biosimilars Market for Breast Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.7. Oncology Biosimilars Market for Lung Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.8. Oncology Biosimilars Market for Colorectal Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.9. Oncology Biosimilars Market for Cervical Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.10. Oncology Biosimilars Market for Blood Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.11. Oncology Biosimilars Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.12. Data Triangulation and Validation
14. MARKET OPPORTUNITIES BASED ON TYPE OF DRUG CLASS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Revenue Shift Analysis
14.4. Market Movement Analysis
14.5. Penetration-Growth (P-G) Matrix
14.6. Oncology Biosimilars Market for Monoclonal Antibodies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7. Oncology Biosimilars Market for Granulocyte Colony-Stimulating Factor: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.8. Oncology Biosimilars Market for Erythropoiesis-Stimulating Agents: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.9. Oncology Biosimilars Market for Immune Modulators: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.10. Oncology Biosimilars Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.11. Data Triangulation and Validation
15. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Oncology Biosimilars Market for Intravenous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.7. Oncology Biosimilars Market for Subcutaneous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.8. Oncology Biosimilars Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.9. Data Triangulation and Validation
16. MARKET OPPORTUNITIES BASED ON END USER
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. Oncology Biosimilars Market for Hospitals: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.7. Oncology Biosimilars Market for Specialty Clinics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.8. Oncology Biosimilars Market for Homecare: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.9. Oncology Biosimilars Market for Other End Users: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.10. Data Triangulation and Validation
17. MARKET OPPORTUNITIES BASED ON DISTRIBUTION CHANNEL
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. Oncology Biosimilars Market for Hospital Pharmacy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.7. Oncology Biosimilars Market for Retail Pharmacy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.8. Oncology Biosimilars Market for Online Pharmacy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.9. Oncology Biosimilars Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.10. Data Triangulation and Validation
18. MARKET OPPORTUNITIES FOR ONCOLOGY BIOSIMILARS IN NORTH AMERICA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. Oncology Biosimilars Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.6.1. Oncology Biosimilars Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.6.2. Oncology Biosimilars Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.6.3. Oncology Biosimilars Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.7. Data Triangulation and Validation
19. MARKET OPPORTUNITIES FOR ONCOLOGY BIOSIMILARS IN EUROPE
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. Oncology Biosimilars Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.1. Oncology Biosimilars Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.2. Oncology Biosimilars Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.3. Oncology Biosimilars Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.4. Oncology Biosimilars Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.5. Oncology Biosimilars Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.6. Oncology Biosimilars Market in Rest of Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.7. Data Triangulation and Validation
20. MARKET OPPORTUNITIES FOR ONCOLOGY BIOSIMILARS IN ASIA-PACIFIC
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. Oncology Biosimilars Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.1. Oncology Biosimilars Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.2. Oncology Biosimilars Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.3. Oncology Biosimilars Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.4. Oncology Biosimilars Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.5. Oncology Biosimilars Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. Data Triangulation and Validation
21. MARKET OPPORTUNITIES FOR ONCOLOGY BIOSIMILARS IN MIDDLE EAST AND NORTH AFRICA (MENA)
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. Oncology Biosimilars Market in Middle East and North Africa (MENA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.1. Oncology Biosimilars Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)
21.6.2. Oncology Biosimilars Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.3. Oncology Biosimilars Market in United Arab Emirates (UAE): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. Data Triangulation and Validation
22. MARKET OPPORTUNITIES FOR ONCOLOGY BIOSIMILARS IN LATIN AMERICA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. Oncology Biosimilars Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.1. Oncology Biosimilars Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.2. Oncology Biosimilars Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.7. Data Triangulation and Validation
23. APPENDIX 1: TABULATED DATA
24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
25. CUSTOMIZATION OPPORTUNITIES
26. ROOTS SUBSCRIPTION SERVICES
27. AUTHOR DETAIL